Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshio Hamashima is active.

Publication


Featured researches published by Yoshio Hamashima.


Cancer Science | 2005

The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-β

Masayoshi Tojo; Yoshio Hamashima; Aki Hanyu; Tetsuya Kajimoto; Masao Saitoh; Kohei Miyazono; Manabu Node; Takeshi Imamura

Transforming growth factor (TGF)‐β signaling facilitates tumor growth and metastasis in advanced cancer. Use of inhibitors of TGF‐β signaling may thus be a novel strategy for the treatment of patients with such cancer. In this study, we synthesized and characterized a small molecule inhibitor, A‐83‐01, which is structurally similar to previously reported ALK‐5 inhibitors developed by Sawyer et al. (2003) and blocks signaling of type I serine/threonine kinase receptors for cytokines of the TGF‐β superfamily (known as activin receptor‐like kinases; ALKs). Using a TGF‐β‐responsive reporter construct in mammalian cells, we found that A‐83‐01 inhibited the transcriptional activity induced by TGF‐β type I receptor ALK‐5 and that by activin type IB receptor ALK‐4 and nodal type I receptor ALK‐7, the kinase domains of which are structurally highly related to those of ALK‐5. A‐83‐01 was found to be more potent in the inhibition of ALK5 than a previously described ALK‐5 inhibitor, SB‐431542, and also to prevent phosphorylation of Smad2/3 and the growth inhibition induced by TGF‐β. In contrast, A‐83‐01 had little or no effect on bone morphogenetic protein type I receptors, p38 mitogen‐activated protein kinase, or extracellular regulated kinase. Consistent with these findings, A‐83‐01 inhibited the epithelial‐to‐mesenchymal transition induced by TGF‐β, suggesting that A‐83–01 and related molecules may be useful for preventing the progression of advanced cancers. (Cancer Sci 2005; 96: 791–800)


Clinical Cancer Research | 2008

A Novel Transforming Growth Factor β Receptor Kinase Inhibitor, A-77, Prevents the Peritoneal Dissemination of Scirrhous Gastric Carcinoma

Hidemi Kawajiri; Masakazu Yashiro; Osamu Shinto; Kazunori Nakamura; Masashige Tendo; Satoru Takemura; Manabu Node; Yoshio Hamashima; Tetsuya Kajimoto; Tetsuji Sawada; Masaichi Ohira; Kosei Hirakawa

Purpose: Transforming growth factor β receptor (TGFβ-R) is reported to correlate with the malignant potential of scirrhous gastric carcinoma. The aim of the current study is to clarify the possibility of molecular target therapy with a TGFβ-R inhibitor, A-77, for the treatment of peritoneal dissemination of scirrhous gastric cancer. Experimental Design: Three scirrhous gastric cancer cell lines and two fibroblasts were used. For in vivo experiments, the A-77 was administered i.p. to mouse models of peritoneal dissemination. The influences of A-77 on the adhesion ability, invasion ability, and the expression of adhesion molecules were examined in vitro. Results: The A-77 administration resulted in a significantly (P < 0.01) better prognosis for the mice with peritoneal dissemination (median survival time, 51 days), compared with the control (median survival time, 25 days). A-77 therefore significantly (P < 0.01) decreased the weight and number of metastatic nodes. The adhesive ability and invasion ability of cancer cells were significantly decreased by A-77. A-77 decreased the expression of α2, α3, and α5 integrins in gastric cancer cells. The histologic findings showed the degree of fibrosis to be less in the tumors treated by A-77. A-77 decreased the growth of fibroblast and invasion-stimulating activity of fibroblasts on cancer cells. Conclusion: The TGFβ-R inhibitor, A-77, decreased the expression of integrins in cancer cells and the proliferation of fibroblasts, which resulted in the decreased adhesive and invasive abilities of scirrhous gastric cancer cells to peritoneum. A-77 is thus considered to be useful for the inhibition of peritoneal dissemination of scirrhous gastric carcinoma.


Bioorganic & Medicinal Chemistry | 2009

Novel 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents

Reiko Tanaka; Hiroko Tsujii; Takeshi Yamada; Tetsuya Kajimoto; Fumio Amano; Junya Hasegawa; Yoshio Hamashima; Manabu Node; Kayoko Katoh; Yutaka Takebe

Sixteen novel compounds; 3alpha-methoxyserrat-14-en-21beta-ol (1) and 3beta-methoxyserrat-14-en-21beta-ol (2) and their curcumin, kojic acid, quercetin, and baicalein conjugates (3)-(18) were designed, synthesized, and evaluated for in vitro anti-HIV-1 reverse transcriptase (RT) activity in infected C8166-CCR5 cells, a human CD4(+) T-lymphocyte cell line. Among them, kojic acid derivatives, 9-12 showed significant biological activity. In particular, the compound 13, the conjugate of two molecules of 3alpha-methoxyserrat-14-en-21beta-ol (1) and one molecule of kojic acid, exerted significant anti-HIV activity with an EC50 value of 0.12microg/mL.


Bioorganic & Medicinal Chemistry | 2014

Synthesis and evaluation of (−)- and (+)-[11C]galanthamine as PET tracers for cerebral acetylcholinesterase imaging

Hiroyuki Kimura; Tomoki Kawai; Yoshio Hamashima; Hidekazu Kawashima; Kenji Miura; Yuta Nakaya; Makoto Hirasawa; Kenji Arimitsu; Tetsuya Kajimoto; Yoshiro Ohmomo; Masahiro Ono; Manabu Node; Hideo Saji

Improved radiopharmaceuticals for imaging cerebral acetylcholinesterase (AChE) are needed for the diagnosis of Alzheimers disease (AD). Thus, (11)C-labeled (-)-galanthamine and its enantiomers were synthesized as novel agents for imaging the localization and activity of AChE by positron emission tomography (PET). C-11 was incorporated into (-)- and (+)-[(11)C]galanthamine by N-methylation of norgalanthamines with [(11)C]methyl triflate. Simple accumulation of (11)C in the brain was measured in an in vivo biodistribution study using mice, whilst donepezil was used as a blocking agent in analogous in vivo blocking studies. In vitro autoradiography of rat brain tissue was performed to investigate the distribution of (-)-[(11)C]galanthamine, and confirmed the results of PET studies in mice. The radiochemical yields of N-methylation of (-)- and (+)-norgalanthamines were 13.7% and 14.4%, respectively. The highest level of accumulation of (11)C in the brains of mice was observed at 10 min after administration (2.1% ID/g). Intravenous pretreatment with donepezil resulted in a 30% decrease in accumulation of (-)-[(11)C]galanthamine in the striatum; however, levels in the cerebellum were unchanged. In contrast, use of (+)-[(11)C]galanthamine led to accumulation of radioactivity in the striatum equal to that in the cerebellum, and these levels were unaffected by pretreatment with donepezil. In in vitro autoradiography of regional radioactive signals of brain sections showed that pretreatment with either (-)-galanthamine or donepezil blocked the binding of (-)-[(11)C]galanthamine to the striatum, while sagittal PET imaging revealed accumulation of (-)-[(11)C]galanthamine in the brain. These results indicate that (-)-[(11)C]galanthamine showed specific binding to AChE, whereas (+)-[(11)C]-galanthamine accumulated in brain tissue by non-specific binding. Thus, optically pure (-)-[(11)C]galanthamine could be a useful PET tracer for imaging cerebral AChE.


Tetrahedron Letters | 1981

One-step synthesis of oxazolinoazetidinones from penicillin sulfoxides: potential intermediates for 1-oxacephem synthesis

Sadao Yamamoto; Susumu Kamata; Nobuhiro Haga; Yoshio Hamashima; Wataru Nagata

Abstract Reaction of penicillin sulfoxides with a tervalent phosphorous compound in the presence of a catalytic amount of squaric acid gave oxazolinoazetidinones, potential intermediates for synthesis of 1-oxacephems, in good yields.2β-Chloromethyl- and 6α-methoxypenicillin sulfoxides also undergo this reaction. The reaction contrasts with the well-known Cooper reaction which usually gives thiazolinoazetidinones.


Tetrahedron Letters | 1979

Synthetic studies on β-lactam antibiotics. 13. Transformation of 6-epipenicillins to 2R-{(1S, 5R)-2-oxa-6-oxo-4,7- diazabicyclo[3.2.0]hept-3-en-7-yl}-3-methylbut-3-enoates

Yoshio Hamashima; Sadao Yamamoto; Shoichiro Uyeo; Mitsuru Yoshioka; Masayuki Murakami; Hisao Ona; Yasuhiro Nishitani; Wataru Nagata

Abstract Reaction of 2β-unsubstituted or functionalized-methyl 6-epipenicillin sulfoxides 2 with tervalent phosphorus compounds gave azetidinone-epi-oxazolines 3 , important intermediates in synthesis of 7α-methoxy-1-oxacephems. Preparation of the 2β-functionalized-methyl substrates is described also.


European Journal of Medicinal Chemistry | 2010

Hybrids of 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2) and various anti-oxidants as cancer chemopreventive agents

Hiroko Tsujii; Takeshi Yamada; Tetsuya Kajimoto; Reiko Tanaka; Harukuni Tokuda; Junya Hasegawa; Yoshio Hamashima; Manabu Node

3alpha-methoxyserrat-14-en-21beta-ol (1) and 3beta-methoxyserrat-14-en-21beta-ol (2) and their conjugates with curcumin, kojic acid, quercetin, and baicalein (3-18), as well as new analogs (19-24) derived from 1 and 2, were tested for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA). The inhibitory effects of 16 (IC50=330 mol ratio/32 pmol/TPA), 9 (IC50=335), 10 (IC50=338), and 15 (IC50=350) were stronger than those of the other compounds and the positive control, oleanolic acid (IC50=449). Compounds 15 and 16, which are conjugates of one molecule each of 1 or 2 and quercetin, inhibited mouse skin tumor promotion in an in vivo two-stage carcinogenesis model. The in vivo two-stage mouse skin carcinogenesis test employed 7,12-dimethylbenz[a]anthracene (DMBA) as an initiator and TPA as a promoter.


Tetrahedron Letters | 1979

Synthetic studies on β-lactam antibiotics. 15. conversion of 7-epicephems into 1-oxacephems☆

Yoshio Hamashima; Tadatoshi Kubota; Koji Ishikura; Wataru Nagata

Abstract 7-Epi-1-oxacephem was obtained by stereospecific, intramolecular etherification of alcohol prepared from 7-epicephems via aldehyde or formate. Synthesis of the 3-acetoxymethyl analogwas unsuccessful. Biologically active 1-oxacephems were derived from by known processes.


PLOS ONE | 2012

Gibberellin Biosynthetic Inhibitors Make Human Malaria Parasite Plasmodium falciparum Cells Swell and Rupture to Death

Tomoko Toyama; Michiru Tahara; Kisaburo Nagamune; Kenji Arimitsu; Yoshio Hamashima; Nirianne Marie Q. Palacpac; Hiroshi Kawaide; Toshihiro Horii; Kazuyuki Tanabe

Malaria remains as one of the most devastating infectious disease, and continues to exact an enormous toll in medical cost and days of labor lost especially in the tropics. Effective malaria control and eventual eradication remain a huge challenge, with efficacious antimalarials as important intervention/management tool. Clearly new alternative drugs that are more affordable and with fewer side effects are desirable. After preliminary in vitro assays with plant growth regulators and inhibitors, here, we focus on biosynthetic inhibitors of gibberellin, a plant hormone with many important roles in plant growth, and show their inhibitory effect on the growth of both apicomplexa, Plasmodium falciparum and Toxoplasma gondii. Treatment of P. falciparum cultures with the gibberellin biosynthetic inhibitors resulted in marked morphological changes that can be reversed to a certain degree under hyperosmotic environment. These unique observations suggest that changes in the parasite membrane permeability may explain the pleiotropic effects observed within the intracellular parasites.


Tetrahedron Letters | 1979

Synthetic studies on β-lactam antibiotics. 19. Synthesis of 3′-nor-type 1-oxacephems☆

Yoshio Hamashima; Sadao Yamamoto; Tadatoshi Kubota; Katsuya Tokura; Koji Ishikura; Kyogi Minami; Fumihiko Matsubara; Masaaki Yamaguchi; Ikuo Kikkawa; Wataru Nagata

Abstract Synthesis of optically active 3′-nor-type 1-oxacephems from 6-APA was described. p -Nitrobenzyl 7β-amino-3-chloro-7α-methoxy-1-oxa-3-cephem-4-carboxylate 39 was also prepared.

Collaboration


Dive into the Yoshio Hamashima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Manabu Node

Kyoto Pharmaceutical University

View shared research outputs
Top Co-Authors

Avatar

Yasuhiro Nishitani

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hiroko Tsujii

Osaka University of Pharmaceutical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge